Status:
Negotiations were not pursued
Manufacturer:
Medison Pharma Canada Inc.
Indication:
Chronic Immune Thrombocytopenia
Last updated May 9, 2022
Status:
Concluded with an LOI
Manufacturer:
Amgen Canada Inc.
Indication:
Multiple Myeloma (including relapsed)
Last updated May 9, 2022
Opsynvi (macitentan and tadalafil)
Status:
Concluded without agreement
Manufacturer:
Janssen Inc.
Indication:
Pulmonary Arterial Hypertension
Last updated May 9, 2022
Status:
Negotiations were not pursued
Manufacturer:
LEO Pharma Inc.
Indication:
Atopic dermatitis
Last updated May 3, 2022
Status:
Negotiations were not pursued
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Atherothrombotic Events in Coronary Artery Disease
Last updated May 3, 2022
Vyxeos (daunorubicin and cytarabine)
Status:
Concluded with an LOI
Manufacturer:
Jazz Pharmaceuticals Canada Inc.
Indication:
Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) or newly diagnosed therapy-related acute myeloid leukaemia (t-AML) , in adults
Last updated April 27, 2022
Status:
Concluded with an LOI
Manufacturer:
HLS Therapeutics Inc.
Indication:
Ischemic events in statin-treated patients
Last updated April 25, 2022
Inqovi (decitabine-cedazuridine)
Status:
Concluded without agreement
Manufacturer:
Taiho Pharma Canada Inc.
Indication:
Myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS with the following French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System (IPSS) groups, in adult patients
Last updated April 22, 2022
Kynmobi (apomorphine hydrochloride)
Status:
Concluded with an LOI
Manufacturer:
Sunovion Pharmaceuticals Canada Inc.
Indication:
Parkinson's disease
Last updated April 4, 2022
Insulin pumps and pump supplies (Insulin pumps and pump supplies)
Status:
Concluded with an LOI
Manufacturer:
Tandem Diabetes Care Canada, Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated March 29, 2022